KOPRAN.NS Stock Analysis
KO
Avoid
Based on Eyestock quantitative analysis, KOPRAN.NS`s fundamental data and valuation indicate an investment grade of Avoid at the current time.
Rating
To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.
Moderate score
Upside
To determine whether the current price is a reasonable to buy a stock, we compare it to our estimate of fair value. The more undervalued a stock is, the higher the upside.
Greatly overvalued
Kopran Ltd. is a holding company, which engages in the manufacturing of pharmaceuticals and related products. The company is headquartered in Mumbai, Maharashtra and currently employs 394 full-time employees. The firm is primarily engaged in the business of manufacturing of formulation (finished dosage form) and active pharmaceutical ingredients (APIs). Its formulations product categories include penicillin-based finished oral dosage forms and non-penicillin-based finished oral dosage forms. The firm's penicillin-based finished oral dosage forms include anti-infective, amoxycillin, ampicillin, cloxacillin and amoxy clauv. Its non-penicillin-based finished oral dosage forms include macrolides, anti-hypertensive, cardiovascular, anti-helmentics, antihistamine, anti-diabetic, pain management and gastroenterology. The company provides ingredients in a wide range of pharmaceutical products, such as capsules, injectables and tablets, among others. The firm's APIs products include anti-hypertensive, macrolides, neuromodulator, urological, anti-infective/anti-acne, sterile carbapenems and sterile cephalosporins.